Navigation Links
Cephalon Reports Another Strong Quarter
Date:10/28/2008

s of our business, sales, earnings and cash flow in light of current general economic conditions; sales, SG&A, R&D, adjusted net income and basic adjusted income per common share guidance for full-year 2008 and full- year 2009; and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe" or other words and terms of similar meaning. Cephalon's performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries as well as more specific risks and uncertainties facing Cephalon such as those set forth in its reports on Form 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward- looking statements. Furthermore, Cephalon does not intend to update publicly any forward-looking statement, except as required by law. The Private Securities Litigation Reform Act of 1995 permits this discussion.

This press release and/or the financial results attached to this press release include "Adjusted Net Income," "Basic Adjusted Income per Common Share," "Adjusted Net Income Guidance," "Basic Adjusted Income per Common Share Guidance," and "Diluted Adjusted Income Per Common Share," amounts that are considered "non-GAAP financial measures" under SEC rules. As required, we have provided reconciliations of these measures. Additional required information is located in the Form 8-K furnished to the SEC in connection with this press release.

CEPHALON, INC. AND SUBSIDIARIES

CONSO
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Cephalon Announces Strong Third Quarter Financial Results
7. Cephalon Submits Supplemental New Drug Application for FENTORA
8. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
9. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
10. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
11. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... 26, 2015 On behalf of biotech client ... Wilentz, Goldman & Spitzer, P.A. (Wilentz) secured a ... Genewiz Inc. in excess of $10 million. The jury ... secrets, and that it improperly hired one or more ... motions for judgment notwithstanding the verdict, a new trial, ...
(Date:2/26/2015)... JOLLA, Calif. , Feb. 26, 2015   ... a biopharmaceutical company leading the discovery and development of ... G. Xanthopoulos , Ph.D., President and Chief Executive Officer ... Cowen and Company 35 th Annual Healthcare Conference ... The conference is being held at the Boston Marriott ...
(Date:2/26/2015)... NJ (PRWEB) February 26, 2015 On ... and its affiliated companies, Wilentz, Goldman & Spitzer, ... a trade secrets lawsuit against Genewiz Inc. in excess ... obtained and utilized GenScript’s trade secrets, and that it ... The court entered an order denying motions for judgment ...
(Date:2/26/2015)... PA (PRWEB) February 26, 2015 ... 9 -12, at the Ernest N. Morial Convention ... exhibitors (count as of February 19, 2015) displaying ... in industrial, academic, and government labs. The Exposition ... as, but not limited to, analytical chemistry; drug ...
Breaking Biology Technology:Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 3Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 2Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 3Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 3Pittcon 2015 Announces Exposition Highlights 2
... , , ... Accera, Inc., a biotechnology company delivering breakthrough therapies in ... genetic interactions impacting the efficacy of the ketogenic compound ... the company,s previously completed double-blind, placebo-controlled trial in patients ...
... ... available, including numerous new features and performance enhancements. , ... Cambridge, MA (PRWEB) July 14, 2009 -- Akaza Research announces the ... rapidly growing open source electronic data capture (EDC) and clinical data management (CDM) software ...
... Whitehead Institute scientists have developed a rapid, inexpensive drug-screening ... until now have stymied drug developers, such as Parkinson,s ... and screen the molecules, cutting target discovery and preliminary ... The current drug discovery process is arduous, requiring ...
Cached Biology Technology:Evidence for a New Genetic Link to Therapeutic Efficacy for Alzheimer's Disease 2Evidence for a New Genetic Link to Therapeutic Efficacy for Alzheimer's Disease 3Evidence for a New Genetic Link to Therapeutic Efficacy for Alzheimer's Disease 4Beta Release of v3.0 of OpenClinica Clinical Trials Software 2Beta Release of v3.0 of OpenClinica Clinical Trials Software 3New method may accelerate drug discovery for difficult diseases like Parkinson's 2New method may accelerate drug discovery for difficult diseases like Parkinson's 3New method may accelerate drug discovery for difficult diseases like Parkinson's 4
(Date:2/5/2015)... FRANCISCO , January 28, 2015 ... Market Analysis, Size And Segment Forecasts To 2020 has ... global IR camera market is expected to reach USD ... by Grand View Research, Inc. IR cameras help identify ... and are expected to witness surging demand in medical ...
(Date:1/22/2015)... Research and Markets ( http://www.researchandmarkets.com/research/4trb7t/biometrics_a ) has announced ... Overview" report to their offering. , ... an individual is who she/he is claiming to be, and ... person,s unique physical characteristics, such as fingerprint, hand or palm ...
(Date:1/22/2015)... MADISON, Wis. , Jan. 15, 2015  BellBrook ... for drug discovery, announced the launch of a ... of the company,s Transcreener UDP Assay, a high ... enzymes. The new assay will allow for sensitive ...
Breaking Biology News(10 mins):IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3Biometrics - A Global Market Overview 2Biometrics - A Global Market Overview 3BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2
... girls exposed to high levels of the pesticide DDT ... to develop hypertension,when they become adults, according to a ... Previous studies have shown that adults exposed ... pressure. But this study, published online March 12 in, ...
... combination of extreme cold temperatures, man-made chemicals and a ... Arctic ozone hole of 2011, a new NASA study ... undergo ozone losses during the winter, the Arctic,s ozone ... Antarctic,s. This is because the three key ingredients needed ...
... was shown that pumpkins and cucumbers can be traced back ... an understanding of Cucurbitaceae evolution and diversity, a new checklist ... information on that family. The study was published in the ... are essential components of a healthy daily diet, not just ...
Cached Biology News:Prenatal exposure to pesticide DDT linked to adult high blood pressure 2NASA pinpoints causes of 2011 Arctic ozone hole 2NASA pinpoints causes of 2011 Arctic ozone hole 3A new checklist confirms Indian origins of pumpkins and cucumbers 2
... Protein Extraction Reagent is a ... that means no scraping, no ... With M-PER Reagent, rapid lysis ... at room temperature, yielding 25% ...
Application: for RNase- decontamination , Registered Trademark of Ambion. ,Special grade: for molecular biology Density: 1.00 g/mL (20 C) Suitab tst: RNase decontamination in accordance...
... meet the needs of the ... medium supports fast cell growth ... while maintaining high cell viability ... using the Baculovirus Expression Vector ...
A set of five proteins which can be used to calibrate a Matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) or Electrospray Ionization (ESI) mass spectrometer....
Biology Products: